EPCAM and neoplasm: In accordance with MRI and CT scan encouraging findings, the tendency of targeted nanocarriers to highly accumulate in the tumor, with less intensity in other organs even at 18 h post-injection, confirmed the active targeting through EpCAM aptamer mediated drug delivery mechanism.